Blockade of immune checkpoints has recently emerged as a novel therapeutic strategy in
various tumors. In particular, monoclonal antibodies targeting programmed cell death 1 (PD …

Immunotherapy with monoclonal antibodies targeting programmed cell death-1 (PD-1) and
programmed cell death ligand-1 (PD-L1) has become a standard of care treatment for …

Immune checkpoint inhibitor (ICI) therapies, including the programmed cell death protein 1
(PD-1) axis blockade, are considered a major oncological breakthrough of the early twenty …

Immunotherapy has emerged as a promising treatment modality in cancer therapy. With
improved understanding of how to tip the balance of immune homeostasis, novel …

Objective Programmed cell death 1 (PD-1) and one of its ligands, PD-L1, are key immune
checkpoint proteins. Evidences showed PD-L1 is an emerging biomarker for immunotherapy …

Blockade of the programmed cell death-1 (PD-1) axis has already been established as an
effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for …

Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …

PD-L1 is expressed in a percentage of lung cancer patients and those patients show
increased likelihood of response to PD-1 axis therapies. However, the methods and assays …

Immunotherapy with programmed death 1 (PD-1)-and programmed death-ligand 1 (PD-L1)-
targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic …

Immunotherapy has become a key strategy for cancer treatment, and two immune
checkpoints, namely, programmed cell death 1 (PD-1) and its ligand (PD-L1), have recently …